217 related articles for article (PubMed ID: 23447620)
1. Increased agonist affinity at the μ-opioid receptor induced by prolonged agonist exposure.
Birdsong WT; Arttamangkul S; Clark MJ; Cheng K; Rice KC; Traynor JR; Williams JT
J Neurosci; 2013 Feb; 33(9):4118-27. PubMed ID: 23447620
[TBL] [Abstract][Full Text] [Related]
2. Biased μ-opioid receptor agonists diversely regulate lateral mobility and functional coupling of the receptor to its cognate G proteins.
Melkes B; Hejnova L; Novotny J
Naunyn Schmiedebergs Arch Pharmacol; 2016 Dec; 389(12):1289-1300. PubMed ID: 27600870
[TBL] [Abstract][Full Text] [Related]
3. Chronic exposure to mu-opioid agonists produces constitutive activation of mu-opioid receptors in direct proportion to the efficacy of the agonist used for pretreatment.
Liu JG; Prather PL
Mol Pharmacol; 2001 Jul; 60(1):53-62. PubMed ID: 11408600
[TBL] [Abstract][Full Text] [Related]
4. Inverse agonists and neutral antagonists at mu opioid receptor (MOR): possible role of basal receptor signaling in narcotic dependence.
Wang D; Raehal KM; Bilsky EJ; Sadée W
J Neurochem; 2001 Jun; 77(6):1590-600. PubMed ID: 11413242
[TBL] [Abstract][Full Text] [Related]
5. SoRI 9409, a non-peptide opioid mu receptor agonist/delta receptor antagonist, fails to stimulate [35S]-GTP-gamma-S binding at cloned opioid receptors.
Xu H; Lu YF; Rice KC; Ananthan S; Rothman RB
Brain Res Bull; 2001 Jul; 55(4):507-11. PubMed ID: 11543951
[TBL] [Abstract][Full Text] [Related]
6. Opioid receptor internalization contributes to dermorphin-mediated antinociception.
Macey TA; Ingram SL; Bobeck EN; Hegarty DM; Aicher SA; Arttamangkul S; Morgan MM
Neuroscience; 2010 Jun; 168(2):543-50. PubMed ID: 20394808
[TBL] [Abstract][Full Text] [Related]
7. Expression of EGFP-amino-tagged human mu opioid receptor in Drosophila Schneider 2 cells: a potential expression system for large-scale production of G-protein coupled receptors.
Perret BG; Wagner R; Lecat S; Brillet K; Rabut G; Bucher B; Pattus F
Protein Expr Purif; 2003 Sep; 31(1):123-32. PubMed ID: 12963349
[TBL] [Abstract][Full Text] [Related]
8. Different effects of opioid antagonists on mu-, delta-, and kappa-opioid receptors with and without agonist pretreatment.
Wang D; Sun X; Sadee W
J Pharmacol Exp Ther; 2007 May; 321(2):544-52. PubMed ID: 17267582
[TBL] [Abstract][Full Text] [Related]
9. Internalization and recycling of human mu opioid receptors expressed in Sf9 insect cells.
Chen LE; Gao C; Chen J; Xu XJ; Zhou DH; Chi ZQ
Life Sci; 2003 May; 73(1):115-28. PubMed ID: 12726892
[TBL] [Abstract][Full Text] [Related]
10. Central HIV-1 Tat exposure elevates anxiety and fear conditioned responses of male mice concurrent with altered mu-opioid receptor-mediated G-protein activation and β-arrestin 2 activity in the forebrain.
Hahn YK; Paris JJ; Lichtman AH; Hauser KF; Sim-Selley LJ; Selley DE; Knapp PE
Neurobiol Dis; 2016 Aug; 92(Pt B):124-36. PubMed ID: 26845176
[TBL] [Abstract][Full Text] [Related]
11. Differential opioid agonist regulation of the mouse mu opioid receptor.
Blake AD; Bot G; Freeman JC; Reisine T
J Biol Chem; 1997 Jan; 272(2):782-90. PubMed ID: 8995364
[TBL] [Abstract][Full Text] [Related]
12. Internalization and down-regulation of mu opioid receptors by endomorphins and morphine in SH-SY5Y human neuroblastoma cells.
Horner KA; Zadina JE
Brain Res; 2004 Dec; 1028(2):121-32. PubMed ID: 15527737
[TBL] [Abstract][Full Text] [Related]
13. Anti-mu opioid antiserum against the third external loop of the cloned mu-opioid receptor acts as a mu receptor neutral antagonist.
Guarna M; Bartolini A; Ghelardini C; Galeotti N; Bracci L; Stefano GB; Bianchi E
Brain Res Mol Brain Res; 2003 Nov; 119(1):100-10. PubMed ID: 14597234
[TBL] [Abstract][Full Text] [Related]
14. Antagonistic property of buprenorphine for putative epsilon-opioid receptor-mediated G-protein activation by beta-endorphin in pons/medulla of the mu-opioid receptor knockout mouse.
Mizoguchi H; Wu HE; Narita M; Hall FS; Sora I; Uhl GR; Nagase H; Tseng LF
Neuroscience; 2002; 115(3):715-21. PubMed ID: 12435410
[TBL] [Abstract][Full Text] [Related]
15. Absence of G-protein activation by mu-opioid receptor agonists in the spinal cord of mu-opioid receptor knockout mice.
Narita M; Mizoguchi H; Narita M; Sora I; Uhl GR; Tseng LF
Br J Pharmacol; 1999 Jan; 126(2):451-6. PubMed ID: 10077238
[TBL] [Abstract][Full Text] [Related]
16. Membrane microviscosity modulates mu-opioid receptor conformational transitions and agonist efficacy.
Emmerson PJ; Clark MJ; Medzihradsky F; Remmers AE
J Neurochem; 1999 Jul; 73(1):289-300. PubMed ID: 10386982
[TBL] [Abstract][Full Text] [Related]
17. Agonist-selective mechanisms of mu-opioid receptor desensitization in human embryonic kidney 293 cells.
Johnson EA; Oldfield S; Braksator E; Gonzalez-Cuello A; Couch D; Hall KJ; Mundell SJ; Bailey CP; Kelly E; Henderson G
Mol Pharmacol; 2006 Aug; 70(2):676-85. PubMed ID: 16682505
[TBL] [Abstract][Full Text] [Related]
18. Endogenous regulator of g protein signaling proteins reduce {mu}-opioid receptor desensitization and down-regulation and adenylyl cyclase tolerance in C6 cells.
Clark MJ; Traynor JR
J Pharmacol Exp Ther; 2005 Feb; 312(2):809-15. PubMed ID: 15383633
[TBL] [Abstract][Full Text] [Related]
19. The mu-opioid receptor gene-dose dependent reductions in G-protein activation in the pons/medulla and antinociception induced by endomorphins in mu-opioid receptor knockout mice.
Mizoguchi H; Narita M; Oji DE; Suganuma C; Nagase H; Sora I; Uhl GR; Cheng EY; Tseng LF
Neuroscience; 1999; 94(1):203-7. PubMed ID: 10613510
[TBL] [Abstract][Full Text] [Related]
20. Chronic agonist treatment converts antagonists into inverse agonists at delta-opioid receptors.
Liu JG; Prather PL
J Pharmacol Exp Ther; 2002 Sep; 302(3):1070-9. PubMed ID: 12183665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
